HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 07-20-2011, 12:20 PM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,765
early phase I results of new Genentech PI3K inhibitor

TGen, Virginia G. Piper Cancer Center studying new breast cancer drug

Promising results of PI3K inhibitor study discussed at ASCO annual meeting

SCOTTSDALE, Ariz. July 20, 2011 A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation by oncologist Dr. Daniel D. Von Hoff at the 47th annual meeting of the American Society of Clinical Oncology (ASCO).

The drug under investigation, GDC-0941, manufactured by Genentech Inc., South San Francisco, Calif., targets the PI3K gene, which is abnormal in about 20-30 percent of patients with advanced breast cancer.

In collaboration with the Karmanos Cancer Institute in Detroit, Mich. and the Dana-Farber Cancer Institute in Boston, Mass., Dr. Von Hoff and his team at Virginia G. Piper Cancer Center Clinical Trials initially tested the drug in 97 patients with various advanced cancers. Patients experienced manageable side effects including diarrhea, nausea, taste alteration, rash, fatigue, itchiness, vomiting and decreased appetite.

The study resulted in significant shrinkage of tumors in two patients - one with advanced cervical cancer and one with advanced breast cancer. Another patient with ampullary cancer of the pancreas is currently on the study with stable disease for more than a year.

Dr. Von Hoff is Physician-In-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen), Chief Scientific Officer at Scottsdale Healthcare and US Oncology. Virginia G. Piper Cancer Center Clinical Trials is a partnership between TGen and Scottsdale Healthcare that treats cancer patients with promising new drugs through clinical trials at the Virginia G. Piper Cancer Center in Scottsdale, Ariz.

"We are very excited about personalizing therapy for breast cancer and gynecologic cancer patients with PI3K inhibitors," said Dr. Von Hoff, who made his presentation in June during ASCO's annual meeting in Chicago. "The next step will be to test samples from breast cancer patients for PI3K mutations and treat those patients accordingly."

Breast cancer remains one of the deadliest cancers among women, with approximately 180,000 new cases each year.
Lani is offline   Reply With Quote
Old 07-20-2011, 12:52 PM   #2
schoonder
Senior Member
 
Join Date: Jul 2008
Posts: 186
Re: early phase I results of new Genentech PI3K inhibitor

Genentech is currently recruiting participants to evaluate this agent (gdc-0941) in conjunction with T-DM1.
http://www.clinicaltrials.gov/ct2/sh...dc-0941&rank=6
schoonder is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 12:52 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2020, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter